SYROS PHARMAC.NEW DL-001
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute mye… Read more
SYROS PHARMAC.NEW DL-001 (0S90) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SYROS PHARMAC.NEW DL-001 (0S90) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SYROS PHARMAC.NEW DL-001 - Net Assets Trend (None–None)
This chart illustrates how SYROS PHARMAC.NEW DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SYROS PHARMAC.NEW DL-001 (None–None)
The table below shows the annual net assets of SYROS PHARMAC.NEW DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SYROS PHARMAC.NEW DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SYROS PHARMAC.NEW DL-001 Competitors by Market Cap
The table below lists competitors of SYROS PHARMAC.NEW DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Emmaus Life Sciences Inc
OTCQB:EMMA
|
$712.27K |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
$712.35K |
|
Hestia Insight Inc
OTCQB:HSTA
|
$712.45K |
|
BOOZ ALLEN HAM-A
BE:BZ9
|
$712.46K |
|
Giant Motorsports Inc
PINK:BZRD
|
$712.16K |
|
Genomic Vision Société Anonyme
F:G09
|
$711.54K |
|
CL8 Holdings Ltd
AU:CL8
|
$711.19K |
|
Taiton Resources Ltd
AU:T88
|
$710.97K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SYROS PHARMAC.NEW DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SYROS PHARMAC.NEW DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SYROS PHARMAC.NEW DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SYROS PHARMAC.NEW DL-001's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SYROS PHARMAC.NEW DL-001 (0S90) | €- | N/A | N/A | $712.24K |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |